Details of issuance or disposal
Issuance of new shares through a third-party allotment (contribution in kind)
Common shares: 9,974,291 shares
The height of each bar represents the proportion of shares received by each allottee. The thin line below represents the number of existing shares to which these shares are added.
¥26,770,997,044
An increase of 9,974,291 shares against 55,843,127 shares outstanding before the capital increase (approximately 17.9%)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of new shares through a third-party allotment (contribution in kind) |
| Number of shares to be issued or disposed of | Common shares: 9,974,291 shares |
| Issue price and disposal price | ¥2,684 per share |
| Total issue value | ¥26,770,997,044 |
| Amount of funds to be raised | ¥26,770,997,044 (estimated net proceeds: Not disclosed) |
| Payment date | 1 July 2026 |
| Intended allottee | Name BCP Asia AYM Holding (Cayman) L.P. / Number of Shares 6,982,004 shares, Name TOHO HOLDINGS CO.,LTD. / Number of Shares 1,994,858 shares, Name Hisamitsu Pharmaceutical Co., Inc. / Number of Shares 997,429 shares |
| Dilution Rate | An increase of 9,974,291 shares against 55,843,127 shares outstanding before the capital increase (approximately 17.9%) |
| Total number of issued shares | 55,843,127 shares → 65,817,418 shares（Approximately 17.9%） |
| Impact on Business Performance | The impact of this matter on the Company's consolidated results for the current fiscal year is currently under review. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To use part of the claims for payment of the consideration for the acquisition of all shares of あゆみ製薬ホールディングス as property contributed in kind.